The Economic Impact of Biosimilars in Oncology and Hematology: The Case of Trastuzumab and Rituximab

Abstract

Combining pharmacological costs of drugs with the measure of efficacy represented by TTF and pCR, biosimilars of rituximab and trastuzumab are cost-effective treatments for advanced follicular lymphoma and breast cancer.